WavePharma Unveils Proprietary Chitosan-Based Delivery System for Controlled Release of Key Ingredients in Personal Care Products

WavePharma, LLC, developer of an innovative, extended release and transdermal delivery technology, WP-ChitosanTM, announced today the launch of its modified chitosan for use in the multi-billion dollar cosmetics and pharmaceutical industries.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
The potential applications of WP-chitosan technology range from extending the efficacy of sunscreen on the skin to creating the ultimate moisturizer that attracts and retains water.

New Orleans, LA (PRWEB) December 11, 2013

WavePharma, LLC, developer of an innovative, extended release and transdermal delivery technology, WP-ChitosanTM, announced today the launch of its modified chitosan for use in the multi-billion dollar cosmetics and pharmaceutical industries. WavePharma is actively seeking development partners to integrate these materials into their personal and skin care formulations.

Native, unmodified chitosan comes from chitin, a natural substance that has been a mainstay in many skin and hair care products for years because of its moisturizing, protective, elastic, antibacterial/antifungal, and biodegradable properties. WavePharma’s modified chitosan retains these properties, plus unlocks premium benefits such as adjustable water retention (hydration), custom bonding of molecules or active ingredients, superior adhesion compared with market leading products, the ability to control the thickness of gels and creams, as well as the ability to control the release of active ingredients and therapeutic agents.

“Our WP-chitosan is more than just a technical advancement, a new feature, or even a new product; it’s a new material. It is chitosan-based, but it’s chemically and physically different than non-modified chitosan and has a number of novel, useful properties to advance skin care, transdermal delivery of active agents, and hair care,” said Jack Foster, CEO of WavePharma.

Much of the WP-chitosan proof-of-concept work to date was sponsored by a market leader in eye medications and focused on controlled release of drugs in the eye. WP-chitosan modified pharmaceutical agents demonstrated long-term retention on the cornea and extended agent delivery profiles and bioavailability. WavePharma is evaluating chitosan-enhanced products for improved retention of actives for the skin and hair. The company has engaged innovation solutions leader Emergent Technologies, Inc. to identify new applications and secure ‘cosmeceutical’ partners looking for science-based solutions for differentiated products using this novel and proprietary delivery system.

“The potential applications of WP-chitosan technology range from extending the efficacy of sunscreen on the skin to creating the ultimate moisturizer that attracts and retains water,” said Kris Looney, Emergent Technologies President. “We anticipate the benefits of this technology will enhance products by improving their performance, satisfying consumer desires for greener products while producing differentiation for our select industry partners increasing their profit margins.”

For additional information about the technology and partnership opportunities, interested parties should visit http://www.wp-chitosan.com.


Contact

  • Cameron Mackie
    Emergent Technologies, Inc.
    512 263 3232
    Email
Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn